Biblio Discovery — Demo Discovery Service

31 hasil untuk "Burger, Michael C"

Menampilkan 21–31 · 0,30 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort

    Rha, Sun Young; Castanon, Eduardo; Gill, Sanjeev dkk.

    Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase 2, multicohort LEAP‐005 study (NCT03797326). METHODS…

  2. Artikel Jurnal Teks lengkap

    CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

    Reardon, David A; Idbaih, Ahmed; Vieito, Maria dkk.

    Neuro Oncol · 2025 · Inggris · PubMed Central

    EO2401, composed of peptide sequences from gut bacteria that cross-react with glioblastoma tumor-associated antigens (IL13Rα2, BIRC5/survivin, and FOXM1) plus a helper peptide, was administered to HLA-A2 positive patients with first progression of a glioblastoma requiring ≤ 2 mg dexamethasone/day…

  3. Artikel Jurnal Teks lengkap

    CTIM-08. FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE

    Tabatabai, Ghazaleh; Freres, Pierre; Glas, Martin dkk.

    Neuro Oncol · 2024 · Inggris · PubMed Central

    INTRODUCTION: CVGBM is an investigational therapeutic mRNA-based vaccine encoding 8 epitopes derived from tumor associated antigens with potential relevance in GBM. This is an ongoing, first-in-human study evaluating the safety of CVGBM in pts with newly-diagnosed MGMT-unmethylated GBM. METHODS…

  4. Artikel Jurnal Teks lengkap

    Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

    Luger, Anna-Luisa; König, Sven; Samp, Patrick Felix dkk.

    J Neurooncol · 2022 · Inggris · PubMed Central

    PURPOSE: Molecular diagnostics including next generation gene sequencing are increasingly used to determine options for individualized therapies in brain tumor patients. We aimed to evaluate the decision-making process of molecular targeted therapies and analyze data on tolerability as well as…

  5. Artikel Jurnal Teks lengkap

    Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas

    Jennewein, Lukas; Ronellenfitsch, Michael W.; Antonietti, Patrick dkk.

    Oncotarget · 2016 · Inggris · PubMed Central

    Recently, the conserved intracellular digestion mechanism ‘autophagy’ has been considered to be involved in early tumorigenesis and its blockade proposed as an alternative treatment approach. However, there is an ongoing debate about whether blocking autophagy has positive or negative effects in…

  6. Artikel Jurnal Teks lengkap

    Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N(2)M(2) umbrella trial

    Wick, Wolfgang; Lanz, Lisa-Marie; Wick, Antje dkk.

    Nat Med · 2025 · Inggris · PubMed Central

    Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT…

  7. Artikel Jurnal Teks lengkap

    Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

    Zeyen, Thomas; Potthoff, Anna-Laura; Nemeth, Robert dkk.

    Trials · 2022 · Inggris · PubMed Central

    BACKGROUND: Glioblastoma is the most frequent and malignant primary brain tumor. Even in the subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and favorable response to first-line therapy, survival after relapse is short (12 months). Standard therapy for recurrent…

  8. Artikel Jurnal Teks lengkap

    Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

    Burger, Michael C; Forster, Marie-Therese; Romanski, Annette dkk.

    Neuro Oncol · 2023 · Inggris · PubMed Central

    BACKGROUND: Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting…

  9. Artikel Jurnal Teks lengkap

    Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

    Boele, Florien W; Frances, Sé M; Darlix, Amélie dkk.

    Neuro Oncol · 2025 · Inggris · PubMed Central

    BACKGROUND: Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors…

  10. Artikel Jurnal Teks lengkap

    Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer

    Talpin, Alice; Maia, Ana; Carpier, Jean-Marie dkk.

    J Immunother Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: Molecular mimicry between commensal bacterial antigens and tumor-associated antigens (TAAs) has shown potential in enhancing antitumor immune responses. This study leveraged this concept using commensal bacterial antigens, termed OncoMimics, to induce TAA-derived peptide (TAAp)-specific…